{
    "clinical_study": {
        "@rank": "157918", 
        "arm_group": {
            "arm_group_label": "RA patients treated by Orencia", 
            "description": "RA patients treated by Orencia according to usual practice from June 1st 2007"
        }, 
        "brief_summary": {
            "textblock": "Database analysis:\n\n        -  To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA)\n\n        -  To describe joint population of Orencia\n\n        -  To assess the impact of the treatment on health status of the treated population as\n           assessed by morbid-mortality criteria\n\n        -  To describe therapeutic strategies and use of health services"
        }, 
        "brief_title": "Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients Diagnosed With a Rheumatoid Arthritis According to ACR Criteria (American College of Rheumatology)", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Observational Model: Historic cohort generated from Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie's\n           (SFR) Orencia and Rheumatoid Arthritis (ORA) registry\n\n        -  Sampling Method: all physicians and sites taking in charge RA patients received an\n           invitation mailing to participate to ORA\n\n        -  Minimum Age: 18 years old at Orencia initiation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult outpatients, male or female aged \u2265 18 years old\n\n          -  Diagnosed with a rheumatoid arthritis according to ACR criteria\n\n          -  Treated with Orencia according to usual practice conditions from June 1st 2007\n\n          -  Agreeing to participate\n\n        Exclusion Criteria:\n\n          -  Patients treated by Orencia in the context of clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients included in SFR's ORA Registry"
            }
        }, 
        "enrollment": {
            "#text": "1031", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694693", 
            "org_study_id": "IM101-364"
        }, 
        "intervention": {
            "arm_group_label": "RA patients treated by Orencia", 
            "description": "No Intervention", 
            "intervention_name": "Orencia", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Abatacept"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 26, 2012", 
        "number_of_groups": "1", 
        "official_title": "Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Haute Autorit\u00e9 de Sant\u00e9 Transparency Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change from DAS28 [C - reactive protein (CRP) and erythrocyte sedimentation rate (ESR)] measured at treatment initiation \u2265 1.2\nDAS28 will be measured every 6 months during 5 years", 
                "measure": "Number of patients with first clinically significant Disease Activity Score (DAS) change", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "description": "EULAR response will be measured every 6 months during 5 years", 
                "measure": "Number of patients with first response to treatment [according to definition of European League Against Rheumatism  (EULAR) response criteria]", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "description": "Change from DAS28 [C - reactive protein (CRP) and erythrocyte sedimentation rate (ESR)] measured at treatment initiation \u2264 3.2\nDAS28 will be measured every 6 months during 5 years", 
                "measure": "Number of patients with first Low Disease Activity State (LDAS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "description": "Change from DAS28 [C - reactive protein (CRP) and erythrocyte sedimentation rate (ESR)] measured at treatment initiation <2.6\nDAS28 will be measured every 6 months during 5 years", 
                "measure": "Number of patients with first Remission state", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Number of patients disease progression with prior improvement", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Number of patients disease progression with no prior improvement", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Number of patients with modification of Orencia administration condition", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Number of patients discontinued and switched from Orencia", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Incidence rate of any type of Adverse events related to Orencia", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "description": "Predefined events are severe infection, thromboembolic events, cancer, lymphoma, other autoimmune disease, cutaneous disorder, significant or persistent disability, death", 
                "measure": "Number of patients with specific predefined events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Response over the time will be assessed over 5 years on EULAR response, LDAS", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694693"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}